Ziyuglycoside I was reported to have anti-cancer effect in a breast cancer cell line through up-regulation of p53 and p21 (Zhu et al., 2016) and Ziyuglycoside II was reported to have anti-cancer activity by induction of reactive oxygen species (ROS) and ROS dependent apoptotic pathways in tumor cell lines (Zhu et al., 2014). The gene discussed is TP53; the disease is breast carcinoma.